Loading clinical trials...
Loading clinical trials...
A Retrospective Observational Non-Interventional Study (NIS) to Assess Patient Characteristics and Healthcare Resource Use (HCRU) Among COVID-19 Patients Receiving Treatment With Nirmatrelvir; Ritonavir (PAXLOVID TM) in the Kingdom of Saudi Arabia (KSA).
The aim of this study is to describe the baseline demographic, clinical characteristics, and Healthcare Resource Use (HCRU) of adult (≥18 years) COVID-19 patients who have been prescribed nirmatrelvir, ritonavir treatment.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
King Faisal Specialist Hospital & research center - Jeddah
Jeddah, Saudi Arabia
King Abdulaziz Medical City
Riyadh, Saudi Arabia
King Faisal Specialist Hospital and Research Center
Riyadh, Saudi Arabia
Start Date
October 17, 2023
Primary Completion Date
April 9, 2024
Completion Date
April 9, 2024
Last Updated
June 5, 2025
250
ACTUAL participants
nirmatrelvir, ritonavir
DRUG
Lead Sponsor
Pfizer
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06631287